the Federal Food, Drug, and Cosmetic Act. Specific guidance can be found in the FDA’s Guidance Document for In Vitro Companion Diagnostic Devices, which outlines the requirements for both premarket submissions and post-market requirements.

Within the EU, the In Vitro Diagnostic Medical Devices Regulation (IVDR) (EU) 2017/746 regulates IVDs, including CDx. This regulation came into force in May 2022 and introduces more stringent requirements to ensure patient safety and effectiveness. Key aspects include classification rules, performance evaluation, and clinical evidence. In the UK, following Brexit, the UK Medical Devices Regulations are enforced by the Medicines and Healthcare products Regulatory Agency (MHRA).

Documentation

The development of a Companion Diagnostic necessitates robust documentation to demonstrate compliance with regulatory requirements. Key components of regulatory submissions may include:

• Device Description: Comprehensive overview providing technical specifications of the diagnostic tool.
• Intended Use Statement: Clearly defined target population and therapeutic products associated with the device.
• Analytical Performance Data: Validation of the diagnostic’s accuracy, precision, specificity, and sensitivity.
• Clinical Performance Data: Evidence demonstrating the clinical utility of the Companion Diagnostic.
• Risk Management Plan: Identification and mitigation of potential risks associated with the use of the diagnostic.

Template Structure for Regulatory Briefing Packs

The following template structure can serve as a guide for Regulatory Affairs teams when creating a regulatory strategy briefing pack for Companion Diagnostics:

1. Executive Summary: A snapshot of the Companion Diagnostic and its therapeutic implications.
2. Regulatory Strategy Overview: Insights into the applicable regulatory pathways and timelines.
3. Data Requirements: Detailed synopsis of preclinical, clinical and post-market documentation needs.
4. Risk Assessment: Overview of risks associated with the development and use of the Companion Diagnostic.
5. Key Regulatory Considerations: Specific regulations and guidelines pertinent to the CDx.
6. Timeline and Milestones: Proposed schedule for submission and anticipated review timelines.

Review/Approval Flow

The review and approval process for Companion Diagnostics involves multiple steps that require close collaboration between Regulatory Affairs and other departments such as Clinical Development, Quality Assurance, and Commercial. Outlined below is an overview of a typical approval flow:

• Pre-Submission Activities: Engaging with regulatory authorities early through pre-submission meetings to clarify expectations and regulatory pathways.
• Development Phase: Gathering clinical data and analytical performance data to support claims made for the CDx.
• Submission Phase: Compilation and submission of regulatory documents to the appropriate authorities (FDA, EMA, MHRA).
• Agency Review: Regulatory bodies review the submission, often engaging in iterative feedback loops with the applicant.
• Approval and Post-Market Surveillance: Once approved, ongoing compliance and real-world evidence collection are crucial for maintaining market authorization.

Common Deficiencies

Understanding typical agency questions and deficiencies can mitigate the risk of prolonged review timelines or rejection. Common areas of concern in submissions for Companion Diagnostics include:

• Lack of Clarity in Intended Use: If the intended use statement is vague, it can lead to misunderstandings about the diagnostic’s purpose.
• Insufficient Analytical Data: Many submissions fail due to inadequate demonstration of analytical validity, which must be rigorously addressed.
• Poor Clinical Evidence Quality: Providing clear, robust clinical data is pivotal; submissions frequently lack this essential component.
• Risk Management Incompleteness: An inadequate risk management plan can lead to serious regulatory concerns.

To avoid these pitfalls, it is critical to ensure comprehensive internal reviews of all documentation and maintain open lines of communication with regulatory authorities throughout the process.

RA-Specific Decision Points

RA teams must navigate specific decision points throughout the lifecycle of regulatory submissions for Companion Diagnostics and their associated therapeutic products. Some of these decision points include:

When to File as Variation vs. New Application

In cases where a CDx is modified (e.g., changes in design, indications, or analytical methods), determining whether to file for a variation or a new application is critical. The following considerations are pertinent:

• Minor Changes: If the change does not affect the device’s intended use or significantly alter its analytical performance, a variation may be appropriate.
• Significant Changes: If the modification impacts the safety or effectiveness of the CDx, it is likely that a new application should be filed.

Justifying Bridging Data

Bridging data may be required when there are differences between the newly proposed diagnostic test and an already approved device. The process involves:

• Demonstrating Equivalence: Provide data showing the new diagnostic achieves similar performance characteristics as the existing device.
• Clinical Context: Justify why the data from the previous CDx is relevant and applicable to the new submitted diagnostic.

Conclusion

Companion Diagnostics present unique opportunities and challenges in the regulatory landscape. A thorough understanding of the legal basis of regulations, meticulous documentation practices, awareness of review processes and common deficiencies, as well as strategic decision-making are critical to navigating this complex terrain successfully. The templates provided may serve as a fundamental resource for RA, CMC, and Labelling teams in preparing effective regulatory strategy briefing packs.

For further reading on international standards and guidelines related to Companion Diagnostics and regulatory affairs, professionals may refer to the ICH guidelines and other relevant regulatory bodies.